HALEOSLABS vs ORCHPHARMA: Stock Comparison

Haleos Labs Limited vs Orchid Pharma Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Orchid Pharma Limited is the larger company by market capitalisation. Haleos Labs Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Orchid Pharma Limited shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Haleos Labs Limited and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HALEOSLABS is more favourable on 9 of 13 scored metrics and ORCHPHARMA on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ORCHPHARMA is the larger company
₹5,072 Cr vs ₹484 Cr
P/E Ratio
HALEOSLABS has a lower P/E
27.94x vs 253.09x
P/B Ratio
HALEOSLABS has a lower P/B
2.27x vs 4.04x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹4.01
Dividend Yield
HALEOSLABS has a higher dividend yield
0.1% vs 0%
Revenue Growth (TTM YoY)
HALEOSLABS has faster revenue growth
0% vs -1.5%
Qtr Sales Growth
ORCHPHARMA has stronger quarterly sales growth
0.05% vs -15.7%
Qtr Profit Growth
ORCHPHARMA has stronger quarterly profit growth
4.26% vs -85.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSORCHPHARMA
SectorHealthcare
IndustryPharmaceuticals

Price

MetricHALEOSLABSORCHPHARMA
Live Price₹1,522.4₹1,000.7
Day Change-3.09%-2.18%
Volume28183,230
52-Week High₹1,774₹1,119.8
52-Week Low₹1,181₹480
Distance from 52W High-14.18%-10.64%

Valuation

MetricHALEOSLABSORCHPHARMA
Market Cap₹484 Cr₹5,072 Cr
P/E Ratio27.94x253.09x
P/B Ratio2.27x4.04x
EPS₹57.3₹4.01
Book Value₹706₹253.98
Dividend Yield0.1%0%

Growth

MetricHALEOSLABSORCHPHARMA
Revenue Growth (TTM YoY)0%-1.5%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-15.7%0.05%
Qtr Profit Growth-85.2%4.26%

Profitability & Leverage

MetricHALEOSLABSORCHPHARMA
ROE8.44%2.12%
ROCE9.91%2.64%
Net Margin5.33%2.51%
Operating Margin13.4%5.07%
Debt to Equity0.52x0.28x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHALEOSLABSORCHPHARMA
Promoter Holding72.11%69.84%
FII Holding0%0.87% 0.3 pp
DII Holding0.31% 0.01 pp20.25% 0.86 pp
Public Holding27.58% 0.02 pp9.05% 0.55 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Haleos Labs Limited and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.